Dataset Information

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

ABSTRACT:

Purpose

To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized.

Methods

We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes.

Results

We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 × 10^-76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 × 10^-3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 × 10^-3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 × 10^-2). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age (P for trend = 2.0 × 10^-3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies (P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer.

Conclusion

These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer risk management of PALB2 PV carriers.

SUBMITTER: Yang X

PROVIDER: S-EPMC7049229 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families.

Yang Xin X Leslie Goska G Doroszuk Alicja A Schneider Sandra S Allen Jamie J Decker Brennan B Dunning Alison M AM Redman James J Scarth James J Plaskocinska Inga I Luccarini Craig C Shah Mitul M Pooley Karen K Dorling Leila L Lee Andrew A Adank Muriel A MA Adlard Julian J Aittomäki Kristiina K Andrulis Irene L IL Ang Peter P Barwell Julian J Bernstein Jonine L JL Bobolis Kristie K Borg Åke Å Blomqvist Carl C Claes Kathleen B M KBM Concannon Patrick P Cuggia Adeline A Culver Julie O JO Damiola Francesca F de Pauw Antoine A Diez Orland O Dolinsky Jill S JS Domchek Susan M SM Engel Christoph C Evans D Gareth DG Fostira Florentia F Garber Judy J Golmard Lisa L Goode Ellen L EL Gruber Stephen B SB Hahnen Eric E Hake Christopher C Heikkinen Tuomas T Hurley Judith E JE Janavicius Ramunas R Kleibl Zdenek Z Kleiblova Petra P Konstantopoulou Irene I Kvist Anders A Laduca Holly H Lee Ann S G ASG Lesueur Fabienne F Maher Eamonn R ER Mannermaa Arto A Manoukian Siranoush S McFarland Rachel R McKinnon Wendy W Meindl Alfons A Metcalfe Kelly K Mohd Taib Nur Aishah NA Moilanen Jukka J Nathanson Katherine L KL Neuhausen Susan S Ng Pei Sze PS Nguyen-Dumont Tu T Nielsen Sarah M SM Obermair Florian F Offit Kenneth K Olopade Olufunmilayo I OI Ottini Laura L Penkert Judith J Pylkäs Katri K Radice Paolo P Ramus Susan J SJ Rudaitis Vilius V Side Lucy L Silva-Smith Rachel R Silvestri Valentina V Skytte Anne-Bine AB Slavin Thomas T Soukupova Jana J Tondini Carlo C Trainer Alison H AH Unzeitig Gary G Usha Lydia L van Overeem Hansen Thomas T Whitworth James J Wood Marie M Yip Cheng Har CH Yoon Sook-Yee SY Yussuf Amal A Zogopoulos George G Goldgar David D Hopper John L JL Chenevix-Trench Georgia G Pharoah Paul P George Sophia H L SHL Balmaña Judith J Houdayer Claude C James Paul P El-Haffaf Zaki Z Ehrencrona Hans H Janatova Marketa M Peterlongo Paolo P Nevanlinna Heli H Schmutzler Rita R Teo Soo-Hwang SH Robson Mark M Pal Tuya T Couch Fergus F Weitzel Jeffrey N JN Elliott Aaron A Southey Melissa M Winqvist Robert R Easton Douglas F DF Foulkes William D WD Antoniou Antonis C AC Tischkowitz Marc M

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20191216 7

<h4>Purpose</h4>To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline <i>PALB2</i> pathogenic variants (PVs) because these risks have not been extensively characterized.<h4>Methods</h4>We analyzed data from 524 families with <i>PALB2</i> PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific ...[more]

PMID: 31841383

Similar Datasets

Project description:BACKGROUND:Germline pathogenic variants in the E-cadherin gene (CDH1) are strongly associated with the development of hereditary diffuse gastric cancer. There is a paucity of data to guide risk assessment and management of families with hereditary diffuse gastric cancer that do not carry a CDH1 pathogenic variant, making it difficult to make informed decisions about surveillance and risk-reducing surgery. We aimed to identify new candidate genes associated with predisposition to hereditary diffuse gastric cancer in affected families without pathogenic CDH1 variants. METHODS:We did whole-exome sequencing on DNA extracted from the blood of 39 individuals (28 individuals diagnosed with hereditary diffuse gastric cancer and 11 unaffected first-degree relatives) in 22 families without pathogenic CDH1 variants. Genes with loss-of-function variants were prioritised using gene-interaction analysis to identify clusters of genes that could be involved in predisposition to hereditary diffuse gastric cancer. FINDINGS:Protein-affecting germline variants were identified in probands from six families with hereditary diffuse gastric cancer; variants were found in genes known to predispose to cancer and in lesser-studied DNA repair genes. A frameshift deletion in PALB2 was found in one member of a family with a history of gastric and breast cancer. Two different MSH2 variants were identified in two unrelated affected individuals, including one frameshift insertion and one previously described start-codon loss. One family had a unique combination of variants in the DNA repair genes ATR and NBN. Two variants in the DNA repair gene RECQL5 were identified in two unrelated families: one missense variant and a splice-acceptor variant. INTERPRETATION:The results of this study suggest a role for the known cancer predisposition gene PALB2 in families with hereditary diffuse gastric cancer and no detected pathogenic CDH1 variants. We also identified new candidate genes associated with disease risk in these families. FUNDING:UK Medical Research Council (Sackler programme), European Research Council under the European Union's Seventh Framework Programme (2007-13), National Institute for Health Research Cambridge Biomedical Research Centre, Experimental Cancer Medicine Centres, and Cancer Research UK.

Project description:BackgroundThe 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is around 5% due to the fact that the majority of patients present with advanced disease that is treatment resistant. Familial pancreatic cancer (FPC) is a rare disorder that is defined as a family with at least two affected first degree relatives, with an estimated incidence of 4%-10%. The genetic basis is unknown in the majority of families although around 10%-13% of families carry germline mutations in known genes associated with hereditary cancer and pancreatitis syndromes.MethodsPanel sequencing was performed of 35 genes associated with hereditary cancer in 43 PDAC cases from families with an apparent hereditary pancreatic cancer syndrome.FindingsPathogenic variants were identified in 19% (5/26) of PDAC cases from pure FPC families in the genes MLH1, CDKN2A, POLQ and FANCM. Low frequency potentially pathogenic VUS were also identified in 35% (9/26) of PDAC cases from FPC families in the genes FANCC, MLH1, PMS2, CFTR, APC and MUTYH. Furthermore, an important proportion of PDAC cases harboured more than one pathogenic, likely pathogenic or potentially pathogenic VUS, highlighting the multigene phenotype of FPC.InterpretationThe genetic basis of familial or hereditary pancreatic cancer can be explained in 21% of families by previously described hereditary cancer genes. Low frequency variants in other DNA repair genes are also present in 35% of families which may contribute to the risk of pancreatic cancer development.FundingThis study was funded by the Instituto de Salud Carlos III (Plan Estatal de I + D + i 2013-2016): ISCIII (PI09/02221, PI12/01635, PI15/02101 and PI18/1034) and co-financed by the European Development Regional Fund ''A way to achieve Europe'' (ERDF), the Biomedical Research Network in Cancer: CIBERONC (CB16/12/00446), Red Temática de investigación cooperativa en cáncer: RTICC (RD12/0036/0073) and La Asociación Española contra el Cáncer: AECC (Grupos Coordinados Estables 2016).